MMS (MMS) Stock Analysis
Verdict: HOLD
Contract disruption overhang masks a 7.4x P/E valuation and 15.7% FCF yield, creating a deep value recovery opportunity.
Investment score: 62/100
Is MMS Stock Worth Reviewing? AI Model Thesis
The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| BR | 16.90 | 6.63 | 2.53 | 11.61 | — | 0.15 |
| SSNC | 21.96 | 2.84 | 2.81 | 11.59 | — | 0.13 |
| EXLS | 21.86 | 6.12 | 2.35 | 12.82 | — | 0.11 |
| CNXC | -1.27 | 0.61 | 0.17 | -19.94 | — | -0.13 |
| VRRM | 12.00 | 2.20 | 0.49 | 5.55 | — | 0.04 |
Should You Buy or Sell MMS Stock? Model Reasoning
The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
MMS Fair Value & Price Target — AI Valuation
- Model Assumptions: ["FY26 consensus EPS of $8.01 and FY27 EPS of $8.36 are achieved without further material contract cancellations.","Free cash flow generation remains above $350M annually ($366.2M in FY25), supporting debt reduction from current $1.44B total debt.","P/E multiple re-rates from 7.7x toward a modest 10.0x–11.0x forward earnings, still representing a discount to peer median P/E of 16.9x–21.8x."]
MMS Risk & Opportunity Analysis
Key Investment Risks
- Permanent Loss of VA Contract Incentives — If paused VA evaluation incentives are permanently removed or reduced, operating margins could compress below the TTM level of 10.9%.
- Government Contract Redetermination and Policy Volatility — Reductions in federal health program budgets or changes in state Medicaid enrollment rules could dampen revenue growth below current forecasts.
- Elevated Financial Leverage Burden — With $1.44B in debt and $260.5M cash (Net Debt/EBITDA of 2.29x), high interest rates increase debt servicing expense upon refinancing.
- Persistent Technical Downtrend Drag — Trading 1.8% above 52-week lows ($51.68) risks continued tax-loss selling and algorithmic momentum dumping if technical support breaches.
Growth Opportunities & Upside Drivers
- Deep Relative Valuation Discount — Trading at 7.45x trailing P/E and 6.08x EV/EBITDA vs peer medians of 16.90x (BR) and 21.86x (EXLS), providing a substantial margin of safety by 2026-09-30.
- Robust Free Cash Flow Generation — Generated $366.16M in FCF for FY2025 (15.7% FCF yield), enabling rapid debt paydown and continuous buybacks/dividends despite headline risks.
- Strong Insider Alignment — CEO Bruce Caswell bought 4,175 shares in Feb 2026 at prices between $76.92 and $78.77, signaling executive confidence 46% above the current $52.61 market price.
- Inelastic Government Program Mandates — Essential administration for Medicaid, Medicare, and ACA programs underpins consensus FY2026 EPS estimates of $8.01.
MMS Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About MMS (MMS)
Is MMS stock a good investment?
The cached TradeMates AI model rates MMS as HOLD with an investment score of 62/100. The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Does MMS pay a dividend?
MMS shows a dividend yield of about 1.43% in the cached stock data. Investors should still verify the latest declared dividend and payout dates.
What does MMS stock do?
B2G (Business-to-Government) outsourced business process services (BPS), administrative support, and IT infrastructure modernization for federal, state, and international public health and welfare programs.
What is MMS stock's price target?
This cached page does not contain a precise model fair value for MMS.
Is MMS stock a buy?
The TradeMates model verdict for MMS is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.
Is MMS a good dividend stock?
MMS may be relevant for dividend investors because the cached data shows a yield near 1.43%, but dividend quality also depends on payout safety, balance sheet strength and cash flow.